10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG) in a report released on Wednesday morning,Weiss Ratings reports.

Other equities analysts have also issued reports about the stock. Barclays cut their price objective on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Citigroup cut their price objective on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group lowered their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, 10x Genomics currently has an average rating of “Hold” and a consensus target price of $20.57.

10x Genomics Stock Down 5.7 %

NASDAQ TXG opened at $10.90 on Wednesday. The company has a market cap of $1.32 billion, a PE ratio of -7.17 and a beta of 1.85. 10x Genomics has a 52 week low of $10.80 and a 52 week high of $48.42. The firm’s 50-day simple moving average is $14.31 and its two-hundred day simple moving average is $17.10.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities research analysts anticipate that 10x Genomics will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. FMR LLC raised its stake in shares of 10x Genomics by 0.6% during the fourth quarter. FMR LLC now owns 13,454,434 shares of the company’s stock worth $193,206,000 after acquiring an additional 86,455 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after acquiring an additional 1,193,712 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of 10x Genomics by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock worth $143,907,000 after acquiring an additional 230,145 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of 10x Genomics during the fourth quarter worth approximately $47,092,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of 10x Genomics by 10.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company’s stock worth $30,394,000 after buying an additional 193,588 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.